These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 33999690)
1. Correction: Type 2 Diabetes. Ann Intern Med; 2021 May; 174(5):735. PubMed ID: 33999690 [No Abstract] [Full Text] [Related]
2. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Ritz E; Laville M; Bilous RW; O'Donoghue D; Scherhag A; Burger U; de Alvaro F; Am J Kidney Dis; 2007 Feb; 49(2):194-207. PubMed ID: 17261422 [TBL] [Abstract][Full Text] [Related]
3. [Correction of endothelial dysfunction in patients with essential hypertension and type 2 diabetes]. Georgian Med News; 2014 Apr; (229):33-40. PubMed ID: 24850603 [TBL] [Abstract][Full Text] [Related]
5. THERAPEUTIC APPROACHES TO THE CORRECTION OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES. Osovska NY; Knyazkova II; Kuzminova NV; Mazur YV; Shchepina NV Wiad Lek; 2020; 73(11):2438-2442. PubMed ID: 33454680 [TBL] [Abstract][Full Text] [Related]
6. Investigation of P213S SELL gene polymorphism in type 2 diabetes mellitus and related end stage renal disease. A case-control study. Stavarachi M; Panduru NM; Serafinceanu C; Moţa E; Moţa M; Cimponeriu D; Ion DA Rom J Morphol Embryol; 2011; 52(3 Suppl):995-8. PubMed ID: 22119815 [TBL] [Abstract][Full Text] [Related]
7. [Possibilities of pharmacological hepatopathy and correction of fat metabolism violations in diabetes mellitus type 1]. Semenova EV Eksp Klin Gastroenterol; 2009; (6):138-42. PubMed ID: 20201297 [TBL] [Abstract][Full Text] [Related]
8. [Specialized food products with modified carbohydrate profile for dietary correction of diet of patients with type 2 diabetes]. Kochetkova AA; Vorobyeva IS; Vorobyeva VM; Sharafetdinov KK; Plotnikova OA; Pilipenko VV; Alexeeva RI; Sasunova AN Vopr Pitan; 2018; 87(6):76-88. PubMed ID: 30763493 [TBL] [Abstract][Full Text] [Related]
9. [Specialized foods with a modified carbohydrate profile in the correction of metabolic disorders in type 2 diabetes]. Sharafetdinov KK; Plotnikova OA; Nazarova AM; Kondratieva OV Vopr Pitan; 2017; 86(6):56-66. PubMed ID: 30592854 [TBL] [Abstract][Full Text] [Related]
10. [EFFECTIVENESS OF CYTOFLAVIN FOR THE CORRECTION OF COGNITIVE IMPAIRMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS]. Gatskikh IV; Veselova OF; Brikman IN; Shalda TP; Varygina EL; Kuznetsov MN; Shul'min AV; Petrova MM Eksp Klin Farmakol; 2015; 78(11):21-5. PubMed ID: 27017701 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of protocol-guided scheduled basal-nutritional-correction insulin over standard care for vascular surgery patients. Harbin M; Dossa A; de Lemos J; Drummond I; Paty B; Taylor B Can J Diabetes; 2015 Jun; 39(3):210-5. PubMed ID: 25639852 [TBL] [Abstract][Full Text] [Related]
12. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345 [TBL] [Abstract][Full Text] [Related]
13. Correction for insulin-dependent diabetes in maternal serum alpha-fetoprotein testing has outlived its usefulness. Evans MI; Harrison HH; O'Brien JE; Dvorin E; Huang X; Krivchenia EL; Reece EA Am J Obstet Gynecol; 2002 Oct; 187(4):1084-6. PubMed ID: 12389009 [TBL] [Abstract][Full Text] [Related]
14. Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB Diabetologia; 2019 May; 62(5):873. PubMed ID: 30899969 [TBL] [Abstract][Full Text] [Related]
15. Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ Diabetologia; 2020 Aug; 63(8):1667. PubMed ID: 32409867 [TBL] [Abstract][Full Text] [Related]
16. Correction: Correction: Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. PLOS ONE Staff PLoS One; 2021; 16(3):e0248441. PubMed ID: 33662010 [TBL] [Abstract][Full Text] [Related]
17. C-peptide measurement in the differentiation of type 1 and type 2 diabetes mellitus--correction and comment. Luqman WA Diabetologia; 1987 May; 30(5):363-4. PubMed ID: 3609528 [No Abstract] [Full Text] [Related]
18. Metabolic Correction as a tool to improve diabetes type 2 management. Miranda-Massari JR; Gonzalez MJ; Fernando AS; Cidre C; Paz IM; Charvel J; Martínez V; Duconge J; Aponte A; Ricart CM Bol Asoc Med P R; 2015; 107(2):54-9. PubMed ID: 26434085 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic objectives and their practical achievement in type 2 diabetes. Keen H J Diabetes Complications; 2000; 14(4):180-4. PubMed ID: 11004425 [TBL] [Abstract][Full Text] [Related]
20. Correction to: The role of melatonin in the onset and progression of type 3 diabetes. Song J; Whitcomb DJ; Kim BC Mol Brain; 2017 Dec; 10(1):59. PubMed ID: 29221469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]